CN102366510A - 一种治疗皮质醇增多症的中药 - Google Patents
一种治疗皮质醇增多症的中药 Download PDFInfo
- Publication number
- CN102366510A CN102366510A CN2011102989698A CN201110298969A CN102366510A CN 102366510 A CN102366510 A CN 102366510A CN 2011102989698 A CN2011102989698 A CN 2011102989698A CN 201110298969 A CN201110298969 A CN 201110298969A CN 102366510 A CN102366510 A CN 102366510A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- chinese medicine
- blood
- hypercortisolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 208000014311 Cushing syndrome Diseases 0.000 title claims abstract description 24
- 208000037171 Hypercorticoidism Diseases 0.000 title claims abstract description 22
- 201000005255 adrenal gland hyperfunction Diseases 0.000 title claims abstract description 22
- 210000000582 semen Anatomy 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 229940023488 pill Drugs 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- -1 electuary Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 241000213006 Angelica dahurica Species 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 241000234653 Cyperus Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241001071917 Lithospermum Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 47
- 210000004369 blood Anatomy 0.000 description 46
- 210000004185 liver Anatomy 0.000 description 17
- 206010040925 Skin striae Diseases 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 13
- 208000002874 Acne Vulgaris Diseases 0.000 description 12
- 206010000496 acne Diseases 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 9
- 208000004611 Abdominal Obesity Diseases 0.000 description 8
- 206010065941 Central obesity Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 206010011655 Cushingoid Diseases 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010020112 Hirsutism Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 210000003516 pericardium Anatomy 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010062315 Lipohypertrophy Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 2
- 229960001140 cyproheptadine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 201000005179 adrenal carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940090003 metopirone Drugs 0.000 description 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗皮质醇增多症的中药,其以重量份计,包含以下组分:柴胡7-11,赤芍12-18,枳壳7-11,香附7-11,川芎7-11,当归7-11,桃仁7-11,红花4-8,丹参12-18,紫草12-18,益母草12-18,甘草2-4。相比于现有技术,本发明的中药针对皮质醇增多症内在病邪,辨症施治,疗效快,成本低,且无毒副作用,效果显著,兼治标本。
Description
技术领域
本发明涉及一种中药,更具体地说,涉及一种治疗皮质醇增多症的中药。
背景技术
库欣综合征(Cushing's syndrome)又称皮质醇增多症(hvpercortisolism)或柯兴综合征,是由多种病因引起的以高皮质醇血症为特征的临床综合征,主要表现为满月脸、多血质外貌、向心性肥胖、痤疮、紫纹、高血压、继发性糖尿病和骨质疏松等。以向心性肥胖,满月脸,皮肤痤疮、紫纹、多毛,糖尿病倾向,高血压症候群,性功能障碍及女性男性化等为主要临床特征。本病多见于女性,男女之比为1:2~1:3,以20~40岁年龄居多。本病预后因病因不同而差异较大,肾上腺癌或异位肿瘤转移者,以及合并心衰、脑血管意外、尿毒症或严重感染者,预后不良。皮质醇增多症属中医的“肝阳”、“痰湿”等范畴。 西医治疗常采用激素合成抑制剂,如甲吡酮,其抑制11-去氧皮质醇转化为皮质醇、11-去氧皮质酮转化为皮质酮,从而使皮质醇合成减少。但作用暂时,只能起缓解症状的作用,或赛庚啶,其是血清素(serotonin)的竞争剂,而血清素可兴奋丘脑-垂体轴而释放ACTH,故赛庚啶可抑制垂体分泌促肾上腺皮质激素(ACTH)。但这些药物存在一定的副作用,价格高昂,且治表不治本。
发明内容
本发明的目的是提供一种治疗皮质醇增多症的中药,其针对皮质醇增多症内在病邪,辨症施治,针对性强,疗效快,成本低,且无毒副作用,能达到标本兼治之效果。
本发明采用以下技术方案:一种治疗皮质醇增多症的中药,以重量份计,包含以下组分:柴胡7-11,赤芍12-18,枳壳7-11,香附7-11,川芎7-11,当归7-11,桃仁7-11,红花4-8,丹参12-18,紫草12-18,益母草12-18,甘草2-4。
本发明中药物的机理分析:
柴胡:苦,微寒。归肝经、胆经。疏散退热,升阳舒肝。用于感冒发热、寒热往来、疟疾、肝郁气滞、胸肋胀痛、脱肛、子宫脱落、月经不调。《医学启源》:柴胡,少阳、厥阴引经药也。妇人产前产后必用之药也。善除本经头痛,非此药不能止。
赤芍:味苦,性微寒。归肝经。具有清热凉血、散瘀止痛的功能。生赤芍以清热凉血力胜。多用于温病热入血分的身热出血,目赤肿痛,痈肿疮毒。泻脾火,降气,行血,破瘀,散血块,止腹痛,退血热,攻痈疮,治疥癞(《滇南本草》)。
枳壳:苦、辛、酸,温。归脾、胃经。理气宽胸;行滞消积。王好古:枳壳主高,枳实主下,高者主气,下者主血,故壳主胸膈皮毛之病,实主心腹脾胃之病,大同小异。
香附:味甘,微寒,无毒。入肝、三焦经。理气解郁,调经止痛。用于肝郁气滞,胸、胁、脘腹胀痛,消化不良,月经不调,经闭痛经,寒疝腹痛,乳房胀痛。《滇南本草》:调血中之气,开郁,宽中,消食,止呕吐。
川芎:味辛,性温。归肝、胆、心包经。活血祛瘀;行气开郁;祛风止痛。《本经》:主中风入脑头痛,寒痹,筋挛缓急,金创,妇人血闭无子。
当归:性温,昧甘、辛。归肝、心、脾经。补血活血,调经止痛,润肠通便。《汤液本草》:当归,入手少阴,以其心主血也;入足太阴,以其脾裹血也;入足厥阴,以其肝藏血也。
桃仁:苦、甘,平。归心、肝、大肠经。活血祛瘀,润肠通便,止咳平喘。用于经闭,痛经,癓瘕痞块,跌扑损伤,肠燥便秘。《用药心法》:桃仁,苦以泄滞血,甘以生新血,故凝血须用。又去血中之热。
红花:性温,味辛。归心、肝经。活血通经,祛瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤。
丹参:味苦;性微寒。归心;心包;肝经。活血祛瘀;调经止痛;养血安神;凉血消痈。可用于热入营血、烦躁不安、心烦失眠、痈疮肿毒。《本经》:主心腹邪气,肠鸣幽幽如走水,寒热积聚;破症除瘕,止烦满,益气。
紫草:性寒,味甘、咸。归心、肝经。凉血、活血,解毒透疹。用于血热毒盛、斑疹紫黑、麻疹不透、疮疡、湿疹、水火烫伤。《纲目》:治斑疹、痘毒,活血凉血,利大肠。
益母草:苦、辛,微寒。归肝、心包经。活血调经,利水消肿,清热解毒。用于月经不调,痛经,经闭,恶露不尽,水肿尿少;急性肾炎水肿。《蒙医传统验方》:除眼翳,且根治虫疾,月经不调,血瘀病,滴虫病等。
甘草:性平,味甘,归十二经。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。
中医认为,皮质醇增多症的病因由情志不遂,劳倦伤脾,肝郁脾虚,湿热内生所致,或因外感六淫,湿热合邪为患,进而化火伤阴,最终阴损及阳,阴阳两虚。亦有素体阴血不足者。
病理变化为恼怒伤肝,肝失条达,肝木侮土,或劳倦伤脾,均致脾气虚损。脾居中土,主运化水湿。肝郁脾虚,湿郁化热,湿热内盛,故见胸背肥胖、满月脸、皮肤痤疮。湿热化火,煎熬津血,津血俱亏,且脾主四肢,脾虚失运,精血不能充养四肢,则四肢消瘦无力。气郁血滞,日久成瘀,溢于肌肤则见紫纹。病久可致肝肾阴亏,阴虚阳亢则发眩晕。最终阴损及阳,致阴阳两虚,形神两衰。
针对气郁血瘀所致的皮质醇增多症,中医认为肝气郁结,情志不得疏泄,故精神抑郁,胸闷喜太息;气郁血滞,日久成瘀,血难上荣,则面色晦滞;血瘀肌肤,则皮肤瘀斑紫纹;血瘀胞宫测月经减少且无规则;舌黯红或有瘀斑,苔薄白,脉弦细或涩,均为气郁血瘀之征。
方中之选者,疏肝理气,活血化瘀,以川芎活血祛瘀、行气开郁,统领全方,为君药;以柴胡升阳舒肝,枳壳、香附理气解郁,赤芍凉血散瘀,相伍为臣,以增强君药活血祛瘀、行气开郁的功效;佐以当归补血活血,桃仁、红花、丹参、紫草、益母草活血祛瘀;甘草为使,甘草和中缓急调和诸药,引药入经以祛顽疾。全方共奏疏肝理气,散瘀活血,平衡机体阴阳。针对皮质醇增多症疗效确切,效果显著,兼治标本。
本发明的中药剂型可以采用片剂、颗粒剂、丸剂、胶囊剂、溶液剂、口服液、口含片、颗粒剂、冲剂、散剂、混悬剂、粉剂。优选地,可以采用溶液剂、颗粒剂、丸剂和胶囊剂。
使用效果
诊断标准:
1、向心性肥胖,呈现出向心性肥胖,即躯干肥而四肢瘦;
2、满月脸,面如满月,且红润多脂;
3、水牛背,背部是“水牛背”模样,腹部悬垂;
4、紫纹,另外还有紫纹,紫纹多见于腹壁、大腿内外侧、臀部的皮肤;
5、性方面,性功能减退,男性阳痿、睾丸变软,女性月经减少、闭经、不育、多毛;
6、骨骼系统,可见骨质疏松,出现腰背痛、脊柱压缩性骨折,后期可因椎体塌陷而成驼背。
疗效评判标准:
1. 痊愈:向心性肥胖症状消失;
2. 有效:向心性肥胖症状缓解,紫纹、痤疮、多毛等症状消失;
3. 无效:上述症状无明显改变。
对40名皮质醇增多症患者(年龄25-40)使用本发明的治疗皮质醇增多症的中药,持续治疗1个疗程(2周),其中12例完全治愈,症状消失;24例症状明显缓解,配胖症状缓解,紫纹、痤疮症状消失;无效4例,总体有效率达90%。治疗无毒副作用,常规化验、肝肾功能检查未见异常。
实例:
患者1:谢某,女性,40岁,身体肥胖、特别是脸部、背部肥胖最为明显,身体轻微浮肿,有痤疮,乏力,攀爬楼梯,气不能续。西药治疗产生了严重的副作用和一定的耐受性,治疗效果不好,后经人介绍使用本发明的中药1个疗程,症状便得以缓解,痤疮减轻,浮肿也消退,继续服药1个疗程,肥胖症状减轻,未出现紫纹和满月脸。
患者2:胡某,女性,34岁,有满月脸,且面部多脂,有痤疮,腹部有紫纹,略现向心性肥胖,典型皮质醇增多症症状。使用本发明的中药1个疗程后,腹部紫纹消退,痤疮基本消失、面部油脂减轻。好转后,继续服药1个月,体重得以下降,可以直观地看到体态基本恢复匀称,不再是满月脸,肥胖症状得到有效控制。
患者3:张某,男性,29岁,肥胖,体重达100kg,且面圆,有痤疮,整个人的外形呈现向心性肥胖,手臂、腹部和大腿部均可见紫纹。服用本发明的中药1个半疗程,痤疮消退,治疗期间叮嘱其注意饮食,多运动,症状好转后,继续服药1个疗程,体重开始下降,痤疮全部消失,紫纹消退,且脸也消瘦下来,体态逐步恢复正常。
具体实施方式
为了更好地理解本发明,下面通过实施例来描述本发明。
实施例1
一种治疗皮质醇增多症的中药,以重量份计,包含以下组分: 柴胡7,赤芍12,枳壳7,香附7,川芎7,当归7,桃仁7,红花4,丹参12,紫草12,益母草12,甘草2。
其制备方法为:
以重量份计,取柴胡7,赤芍12,枳壳7,香附7,川芎7,当归7,桃仁7,红花4,丹参12,紫草12,益母草12,甘草2;将上述中药洗净,去杂质,放入容器加水没过药材浸泡,30分钟后,大火煎煮至沸腾,然后文火慢熬1小时;将药汁滤出,分袋包装,一袋200ml,早晚各服一袋,可兼用药液涂抹患部。
实施例2
一种治疗皮质醇增多症的中药,以重量份计,包含以下组分:柴胡11,赤芍18,枳壳11,香附11,川芎11,当归11,桃仁11,红花8,丹参18,紫草18,益母草18,甘草4。
其制备方法为:
以重量份计,取柴胡11,赤芍18,枳壳11,香附11,川芎11,当归11,桃仁11,红花8,丹参18,紫草18,益母草18,甘草4;洗净,干燥,将上述药材混合,每公斤加入大约10L水,文火煎0.5-1小时,大火煎1-2小时;取煎液过150目筛,后用浓缩器浓缩至相对密度1.10-1.20的清膏,取2/3清膏在120℃下喷雾干燥,得清膏粉末,将粉末与剩余1/3清膏混合,制粒;颗粒分装机分装,即得颗粒剂。
实施例3
一种治疗皮质醇增多症的中药,以重量份计,包含以下组分: 柴胡9,赤芍15,枳壳9,香附9,川芎9,当归9,桃仁9,红花6,丹参15,紫草15,益母草15,甘草3。
其制备方法为:
以重量份计,取柴胡9,赤芍15,枳壳9,香附9,川芎9,当归9,桃仁9,红花6,丹参15,紫草15,益母草15,甘草3;洗净,干燥,将上述药材混合,用粉碎机粉碎为150-180目细粉,加入适当蜂蜜混合,制丸机制丸,低温干燥,分装,即得丸剂。
实施例4
一种治疗皮质醇增多症的中药,以重量份计,包含以下组分: 柴胡9,赤芍15,枳壳9,香附9,川芎9,当归9,桃仁9,红花6,丹参15,紫草15,益母草15,甘草3。
其制备方法为:
以重量份计,取柴胡9,赤芍15,枳壳9,香附9,川芎9,当归9,桃仁9,红花6,丹参15,紫草15,益母草15,甘草3;洗净,干燥,将上述药材混合,每公斤加入大约10L水,文火煎0.5-1小时,大火煎1-2小时;取煎液过150目筛,后用浓缩器浓缩至相对密度1.10-1.20的清膏,取2/3清膏在120℃下喷雾干燥,得清膏粉末,将粉末与剩余1/3清膏混合,制粒;将颗粒用胶囊填充剂制成0.4g/粒胶囊。
Claims (4)
1.一种治疗皮质醇增多症的中药,其特征在于,以重量份计,包含以下组分: 柴胡7-11,赤芍12-18,枳壳7-11,香附7-11,川芎7-11,当归7-11,桃仁7-11,红花4-8,丹参12-18,紫草12-18,益母草12-18,甘草2-4。
2.根据权利要求1所述的中药,其特征在于,以重量份计,优选包含以下组分:柴胡9,赤芍15,枳壳9,香附9,川芎9,当归9,桃仁9,红花6,丹参15,紫草15,益母草15,甘草3。
3.根据权利要求1所述的中药,其特征在于,所述中药采用片剂、颗粒剂、丸剂、胶囊剂、溶液剂、口服液、口含片、颗粒剂、冲剂、散剂、混悬剂、粉剂。
4.根据权利要求1所述的中药,其特征在于,所述中药优选采用溶液剂、颗粒剂、丸剂和胶囊剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102989698A CN102366510A (zh) | 2011-09-29 | 2011-09-29 | 一种治疗皮质醇增多症的中药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102989698A CN102366510A (zh) | 2011-09-29 | 2011-09-29 | 一种治疗皮质醇增多症的中药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102366510A true CN102366510A (zh) | 2012-03-07 |
Family
ID=45759130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102989698A Pending CN102366510A (zh) | 2011-09-29 | 2011-09-29 | 一种治疗皮质醇增多症的中药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102366510A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432237A (zh) * | 2013-08-17 | 2013-12-11 | 广州市云桥生物科技有限公司 | 一种治疗皮质醇增多症的中药有效部位组合物 |
| CN118490756A (zh) * | 2024-05-17 | 2024-08-16 | 湖北福人金身药业有限公司 | 一种基于硼簇基的皮质醇分泌抑制剂及其制备方法与应用 |
-
2011
- 2011-09-29 CN CN2011102989698A patent/CN102366510A/zh active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432237A (zh) * | 2013-08-17 | 2013-12-11 | 广州市云桥生物科技有限公司 | 一种治疗皮质醇增多症的中药有效部位组合物 |
| CN103432237B (zh) * | 2013-08-17 | 2014-11-05 | 张群 | 一种治疗皮质醇增多症的中药组合物 |
| CN118490756A (zh) * | 2024-05-17 | 2024-08-16 | 湖北福人金身药业有限公司 | 一种基于硼簇基的皮质醇分泌抑制剂及其制备方法与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105477616A (zh) | 一种清心安神、化痰醒脑及活血通络的药物及制备方法 | |
| CN103977358A (zh) | 一种降脂护肝的口服中药 | |
| CN106267120A (zh) | 一种治疗鼻炎的中药制剂及其制备方法 | |
| CN105535471A (zh) | 一种用于治疗神经衰弱的丸剂药物及其制备方法 | |
| CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
| CN102366468A (zh) | 一种治疗白癜风的中药 | |
| CN101085308B (zh) | 一种口服治疗乳腺癌的中药汤剂 | |
| CN102048893A (zh) | 一种治疗痹症的中药组合物 | |
| CN103623280B (zh) | 一种治疗心脑血管疾病的中药制剂 | |
| CN102366516A (zh) | 一种治疗皮质醇增多症的中药组合物 | |
| CN103638234B (zh) | 一种治疗耳鸣的中药组合物、制剂及其制备方法 | |
| CN103083616B (zh) | 一种治疗卵巢囊肿的中药 | |
| CN105031331A (zh) | 一种治疗痛经的肚脐贴剂及其制备方法 | |
| CN102366510A (zh) | 一种治疗皮质醇增多症的中药 | |
| CN104721758A (zh) | 一种治疗卵巢囊肿的药物及其制备方法 | |
| CN103536849A (zh) | 治疗肺栓塞的药物及其制备方法 | |
| CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
| CN104116801A (zh) | 一种治疗盆腔淤血综合征的中成药 | |
| CN102366554A (zh) | 一种治疗皮质醇增多症的中药制剂 | |
| CN102366469A (zh) | 一种治疗白癜风的药物 | |
| CN105999110A (zh) | 一种用于治疗女性慢性盆腔疼痛的中药冲剂及制备方法 | |
| CN103961658A (zh) | 一种降脂护肝的胶囊制剂 | |
| CN103948713A (zh) | 一种治疗高血压的中药组合物 | |
| CN104116805A (zh) | 一种治疗盆腔淤血综合征的中药制剂 | |
| CN103263645B (zh) | 一种治疗胃炎、胃溃疡的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120307 |